"They found that about 68% of the patients with a PSA less than 1 actually had a positive test. And that's really important," says Jason M. Hafron, MD.
In an interview with Urology Times at the 2023 LUGPA Annual Meeting, Jason M. Hafron, MD, highlights data from a recent post-hoc analysis of the SPOTLIGHT trial exploring flotufolastat F 18 (Posluma) in patients with suspected biochemical recurrence who have low to very low PSA levels. Hafron is the chief medical officer and medical director of clinical research at the Michigan Institute of Urology, PC, and a professor of urology at the William Beaumont School of Medicine, Oakland University.
Video Transcript:
The SPOTLIGHT trial with Posluma, they did a post hoc analysis at ASTRO just recently. It's interesting; they looked at a segment of the study with the patients with very low PSAs. They found that about 68% of the patients with a PSA less than 1 actually had a positive test. And that's really important. It's important at multiple levels. It's important in the clinic, when you're counseling a patient to say that two-thirds of the time, we're going to find something on this test, and this test is worth it. It's also important when we're in the early stages of PET imaging, working with the payers, because sometimes we get push back at testing too early. I think based on the Posluma post hoc analysis, or the SPOTLIGHT post hoc analysis, it's pretty clear that we're finding disease. They even broke it down to less than .5. Even at .5 PSA, they were getting 64% positivity, and almost 30% extra prostatic spread, or out of the pelvis spread. So, there's significant disease that Posluma is finding in a very low PSA. In my practice, I just try to PET everyone early and as early as possible, because it can really make a difference in the management of these patients.
This transcription has been edited for clarity.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.
2-year data show continued enfortumab vedotin efficacy in cisplatin-ineligible MIBC
June 3rd 2024Updated findings from cohort H of the EV-103 study showed promising 2-year event-free survival outcomes and favorable antitumor activity with enfortumab vedotin in cisplatin-ineligible patients with muscle-invasive bladder cancer.
TKIs show modest activity in lenvatinib-exposed patients with advanced renal cell carcinoma
June 2nd 2024Patients with advanced renal cell carcinoma treated with TKIs in the second or third line following lenvatinib treatment showed modest activity, highlighting the need for improved treatment options.
Sacituzumab Govitecan yields ‘limited efficacy’ post-EV in real-world mUC study
June 2nd 2024A retrospective cohort of patients with metastatic urothelial cancer who received prior enfortumab vedotin had low efficacy when treated with sacituzumab govitecan, with the best outcomes coming from directly sequencing the 2 agents.